Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Skin Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 7fludarabine 4Dasatinib 2zimberelimab 1pembrolizumab 1palbociclib 1olaparib 1fluorodopa F 18 1Vincristine 1Vemurafenib 1Topotecan 1Temozolomide 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Magnetic Resonance Spectroscopy 1Influenza Vaccines 1Fluoxetine 1Fluorodeoxyglucose F18 1Everolimus 1Etoposide 1Doxorubicin 1Decitabine 1Cholestanetriol 26-Monooxygenase 1CVAD protocol 1Busulfan 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Recurrence × Influenza Vaccines × Clear all
NCT04626752 2020-11-13

CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

Hebei Senlang Biotechnology Inc., Ltd.

Phase EARLY_PHASE1 Unknown
50 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡